Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Peel Hunt
$23.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sphere Medical Holding PLC Announces Positive Results From Point Of Care Pelorus 1500 Study


Friday, 23 Nov 2012 02:00am EST 

Sphere Medical Holding PLC announced that Pelorus 1500, the in-vitro diagnostic medical device for the rapid measurement of the intravenous anaesthetic propofol at the point of care, has met its primary end point in a clinical study and has demonstrated equivalent performance to a gold standard method of analysis. A total of 111 whole blood samples from 32 patients undergoing cardiopulmonary bypass surgery at the Papworth Hospital, Cambridge, UK were analysed. Each sample was tested using both Sphere Medical's Pelorus 1500 and the current gold standard High Performance Liquid Chromatography (HPLC) reference test. The results from the Pelorus 1500 showed excellent agreement with the reference method (1). 

Company Quote

25.5
0.0 +0.00%
21 Jul 2014